Assessing the Challenges Associated with the Administration Method of the AAV Therapy

Time: 2:00 pm
day: Day Two


• Exploring clinical data to gain a better understanding of AAV2 safety

• Highlighting important safety events identified and how to best mitigate these going forward

• Comparing the safety of administration method in ophthalmic gene therapies